Gozewijn D. Laverman

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial

Maartje C.J. Slagman, Femke Waanders, Marc H. Hemmelder et al. · BMJ · 2011 · 284 citations · Full text

Medicine, Nephrology, Pharmacotherapy +17

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

David Z.I. Cherney, Claire C. J. Dekkers, Sean J. Barbour et al. · The Lancet Diabetes & Endocrinology · 2020 · 274 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers

Claire C. J. Dekkers, S. Petrykiv, Gozewijn D. Laverman et al. · Diabetes Obesity and Metabolism · 2018 · 258 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial

Nete Tofte, Morten Lindhardt, Katarina Adamova et al. · The Lancet Diabetes & Endocrinology · 2020 · 254 citations · Full text

Medicine, Endocrinology, Nephrology +17